Diagnostic Tool Reduces Chemotherapy Rates Post-Surgery In Women With Breast Cancer

In what's believed to be one of the largest population-based studies of Oncotype DX ever conducted, researchers at The University of Texas MD Anderson Cancer Center have found that the commercial diagnostic tool, Oncotype DX, was associated with a decrease in chemotherapy use in younger patients, but not in those over 66 years of age.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news